Praxis Precision Medicines, Inc. Stock Price, News & Analysis

Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on CNS disorders, has granted restricted stock units (RSUs) to a new non-executive employee. The Compensation Committee approved an award of 750 RSUs on June 2, 2025, under the company's 2024 Inducement Plan. The RSUs will vest over four years in equal annual installments, contingent on continued employment. This grant was made in accordance with Nasdaq Listing Rule 5635(c)(4), which allows for equity awards to new employees as employment inducement. The 2024 Inducement Plan is specifically designed for granting equity awards to individuals who were not previously Praxis employees.

Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on developing CNS disorder therapies, has announced its participation in three upcoming investor conferences:

• H.C. Wainwright BioConnect Conference - Fireside chat on May 20th at 9:30am ET at NASDAQ
• Mizuho Neuro & Ophthalmology Summit - Participation on May 21st in New York City
• Jefferies Global Healthcare Conference - Corporate overview presentation on June 4th at 8:10am ET at Marriott Marquis, NYC

The company will be available for one-on-one meetings during all events, with webcasts available for select presentations through the company's website for 90 days.

Praxis Precision Medicines (NASDAQ: PRAX) hosted a virtual investor event highlighting updates on their developmental and epileptic encephalopathies (DEEs) clinical programs. Key highlights include:

Their lead drug relutrigine showed promising results in the EMBOLD study, with patients achieving ~90% seizure reduction and extending seizure-free periods from 3 to 67 days after 11 months. The company plans to initiate the EMERALD registrational study in mid-2025, targeting a US market potential of $3+ billion.

For elsunersen, the EMBRAVE3 registrational trial will begin mid-2025, initially enrolling patients ages 2-18 with plans to extend to newborns. The global market potential is estimated at $1 billion with 5,000 addressable patients.

In their pipeline, Praxis expects to nominate development candidates for PRAX-100 (targeting monogenetic autism) by mid-2025, and PRAX-080 and PRAX-090 by end of 2025.

Praxis Precision Medicines (NASDAQ: PRAX) has granted restricted stock unit (RSU) awards to five new non-executive employees under its 2024 Inducement Plan. The awards cover a total of 3,688 shares of common stock and were approved by the Compensation Committee on May 1, 2025. The RSUs will vest over four years in equal annual installments, contingent on continued employment.

The grants were made as employment inducements in accordance with Nasdaq Listing Rule 5635(c)(4). Praxis, a clinical-stage biopharmaceutical company, focuses on developing therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance.

Praxis Precision Medicines (NASDAQ: PRAX) reported significant progress in its CNS disorder treatment pipeline and Q1 2025 financial results. The company maintains a strong financial position with $472 million in cash, providing runway into 2028. Key developments include:

• Six major study readouts expected across four programs in next 12 months • Preparing to launch pivotal studies for two DEE programs: EMERALD and EMBRAVE3 • Vormatrigine showing promising safety profile with no food effect • RADIANT study topline results expected by mid-2025 • Essential3 program for ulixacaltamide continuing despite interim analysis recommendation

Financial highlights for Q1 2025: • Net loss of $69.3M vs $39.6M in Q1 2024 • R&D expenses increased to $60.8M from $27.0M YoY • G&A expenses decreased to $13.9M from $15.3M YoY • 20.3M shares outstanding as of March 31, 2025

Praxis Precision Medicines (NASDAQ: PRAX) has announced a virtual investor event scheduled for May 2, 2025, from 10:00 a.m. to 11:30 a.m. EDT. The webinar will focus on the company's clinical programs in developmental and epileptic encephalopathies (DEEs).

The presentation will cover three key clinical studies:

• The EMBOLD study evaluating relutrigine for SCN2A and SCN8A DEEs
• The EMERALD study evaluating relutrigine for broader DEEs
• The EMBRAVE3 study evaluating elsunersen for SCN2A gain-of-function DEE

The event will be hosted by the Praxis management team, with a replay available on the company's website for 90 days under the 'Events & Presentations' page.

Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on developing CNS disorder therapies, has announced its participation in two major investor conferences in April 2025.

The company will present a corporate overview at the 24th Annual Needham Virtual Healthcare Conference on April 7, 2025, at 11:00 a.m. EDT, which will be available via webcast. Additionally, Praxis management will attend the Piper Sandler Spring Biopharma Symposium in Boston on April 17, 2025, offering one-on-one meeting opportunities.

Investors interested in meetings should contact their Needham or Piper Sandler representatives. Webcast replays will be accessible through the company's website's 'Events & Presentations' page for 90 days.

Praxis Precision Medicines (Nasdaq: PRAX) has announced the granting of restricted stock unit awards to four new non-executive employees. The Compensation Committee of Praxis' Board of Directors approved these grants on April 1, 2025, under the company's 2024 Inducement Plan.

The awards cover an aggregate of 8,763 shares of common stock and will vest in four equal annual installments, contingent upon continued employment. These equity awards were granted as employment inducements in accordance with Nasdaq Listing Rule 5635(c)(4), specifically designed for new hires who were not previously Praxis employees.

Praxis Precision Medicines (NASDAQ: PRAX) has announced its participation at the American Academy of Neurology (AAN) 2025 Annual Meeting from April 5-9, 2025, in San Diego. The company will present data from four late-stage programs focused on epilepsy and movement disorders.

The presentations include updates on the vormatrigine ENERGY program and newly initiated clinical trials across the U.S., Europe, and Latin America. Praxis will host an In-Booth Speaker Showcase featuring experts in CNS disorders at booth #2113.

Key presentations include:

• Two posters on Essential Tremor management and clinical trial characteristics for ulixacaltamide
• An observational study on epilepsy monitoring (EMPOWER)
• Updates from the Phase 1 trial of vormatrigine

The company will also host networking events and daily speaker showcases from April 6-9, focusing on revolutionizing CNS therapies.